Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared insights from ASH25 Annual Meeting on X:
“Meeting colleagues from Medical College of Wisconsin always refreshes the vibes of our fellowship days.”
“Thank you HealthTree for your efforts to raise awareness among patients on ongoing research in blood cancers and leukemia.”
“ASH25 outcome post Menin Inhibitor – data on 84pts. -median OS 4.4mo, better in Venetoclax naive patients.”
“ASH25 “decoding DDX41 mutant HR-MDS and AML”
Conclusion:
1. Not every DDX41-mutant HR-MDS/AML responds well to venetoclax plus HMA.
2. no survival difference between pathogenic vs VUS variants.
3. Splicing-factor co-mutations predicted worse outcomes, while allo-HCT trended better.
Highlights need for larger cohorts to refine predictors.”
“Our traditional COMMAND Consortium meetup at ASH25 – always a highlight. So proud of this incredible group.”
“ASH25 Dr. Kristen O’Dwyer presenting “immune targeting in Ph+/Ph- B-cell ALL.”
“ASH25: Dr. Uma Borate presented data on Ven+AZA in therapy related MDS.”
“Subset analysis from VERONA trial presented by Dr. Garcia-Manero: venetoclax plus AZA combination showed trend towards better response rate and OS in younger pt, high IPSS-R and high BM blast.”
“Phase III GIMEMA ALL2820: chemo-free targeted/immunotherapy beats TKI/chemo:
•Higher CHR + MRD responses, fewer deaths, better EFS/OS
•More MRD negativity + fewer relapses vs prior trial
•Crossover helps rescue MRD+ patients
•Biology-driven transplant strategy effective
•Chemo-free approach emerging as new standard for adult Ph+ ALL.”
Summary: Ponatinib showed a trend toward higher molecular response vs. imatinib in older Ph+ ALL patients Safety and tolerability were similar between ponatinib and imatinib Longer follow-up needed to assess survival impact.”
“Anand Patel present data on InO plus dasatinib for Ph+ ALL:
Summary:
High ≥MR3 rates after 2 cycles of dasatinib + InO
VOD seen only in Schema 1; none in Schema 2
Switching to ponatinib boosts depth of response
100% achieved MR4 or NGS-MRD– by Course 3
76% EFS at 2.1 yrs; 0 CNS relapses; no allo-HCT
Efficacy/safety similar to TKI + blinatumomab.”
“Ibrahim Aldoss CAR T-cell consolidation in elderly B-cell ALL. Encouraging results and tolerability.”
“ALL long-term follow up of Alliance A041703 study (Inotuzumab followed by Blinatumomab) 3 yrs OS 59%.”
“Outcomes of pregnancies in sickle cell patients treated with hydroxyurea: Findings from the escort-HU cohort studies: among 245 pregnancies with SCD. No maternal deaths or malformations noticed.”
“Dr. Lindsley introducing 4 plenary DNA damage response (DDR) mutant clonal hematopoiesis TP53, PPM1D, ATM, CHEK2 CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.”
“Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections IV iron safe during infection and shown to improve outcome. Dr. Haris Sohail Awesome job!”
“Dr Wei: introducing the plenary PARADIGM trial!”
“PARADIGM trial. Great work, congratulations to Dr. Fathi and colleagues!
Summary:
The study met PE for EFS.
Higher ORR and CR in VEN+AZA gp
More pt received transplant in VEN+AZA gp
Better QOL.”
“Enzomenib (menin inhibitor) in R/R Acute Leukemia. Presented by Dr. Naval Daver
Summary: Suggest to have better CR rates and duration of response.”
“ASH25: Dr. Justin Watts Menin Inhibitors Enzomenib plus Venetoclax (14 days) + Azacitidine in RR AML.”
“KOMET007 “upfront Ziftomenib plus VEN+AZA in intensive ineligible NPM1-mutant treatment naive.”
“KOMET007: Ziftomenib + VEN/AZA in RR AML Ziftomenib + ven/aza shows good tolerability and promising activity in R/R AML with NPM1-mut or KMT2A-rearranged disease. ORR up to 65% (NPM1-m) and 41% (KMT2A-r), with higher responses in ven-naïve.”
“Largest cohort to date of de novo BCR::ABL1⁺ AML. Entity shows strong association with adverse cytogenetic and molecular abnormalities.
Adding a BCR::ABL TKI to intensive chemotherapy significantly improves outcomes:
•CR/CRi: 90% vs 67%.
•5-year OS: 63% vs 39%.
•TKI + intensive chemo should be standard of care for eligible patients.
Two-thirds of patients treated with TKI + intensive chemo without allo-HSCT did not relapse. Future ELN classification should no longer categorize de novo BCR::ABL1⁺ AML as adverse.”
“3+7 and Ivosidenib in newly diagnosed IDH1m AML.
Conclusion IVO-based induction, consolidation, and maintenance produced durable remissions, acceptable safety, and strong long-term survival. High response rates and reliable blood count normalization were observed, with nearly half of patients able to proceed to transplant. Outcomes were similar across treatment arms, and the regimen is now being tested in a phase 3 randomized trial.”
“Pivekimab (anti-CD123 ADC) plus Venetoclax/Azacitidine. Presented by Dr. Naval Daver.”
“AZA/VEN plus TAG in newly diagnosed in RR BPDCN presented by Dr. Andy Lane.”
More posts featuring Talha Badar on OncoDaily.
